Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease

Blood

Volumn 126, Issue 4, 2015, Pages 546-557

  Byung Su, Kim ^a,b   Hidekazu, Nishikii ^a,c   Jeanette, Baker ^a   Antonio, Pierini ^a   Dominik, Schneidawind ^a   Yuqiong, Pan ^a   Andreas, Beilhack ^d,e   Chung Gyu, Park ^b   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA DR3 ANTIGEN; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY; CYTOKINE; DEATH RECEPTOR 3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOGLOBULIN; TNFRSF25 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMATIC REVIEW; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DONOR; FEMALE; FLUORESCENCE MICROSCOPY; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VS HOST DISEASE; IMMUNOLOGY; LYMPHOMA, B-CELL; METABOLISM; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; IMMUNOGLOBULINS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED;

EID: 84938259172     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-637587     Document Type: Article

References (46)

1. Randolph DA, Fathman CG. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annu Rev Med. 2006;57:381-402.
2. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graftversus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
3. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graftversus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
4. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
5. Jones SC, Murphy GF, Korngold R. Posthematopoietic cell transplantation control of graftversus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003; 9(4):243-256.
6. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3): 1061-1070.
7. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-3928.
8. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
9. Schneidawind D, Pierini A, Negrin RS. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood. 2013;122(18):3116-3121.
10. Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol. 2011; 23(6):462-468.
11. Cao T, Soto A, Zhou W, et al. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol. 2009;258(1):65-71.
12. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83): 83ra41.
13. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007;178(1):320-329.
14. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graftversus-host disease. Am J Transplant. 2011; 11(6):1148-1157.
15. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graftversus-leukemia. Blood. 2010;116(1):129-139.
16. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp31 regulatory T cells with histone deacetylase inhibitors. Cell Immunol. 2009; 257(1-2):97-104.
17. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood. 2011;118(8):2342-2350.
18. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271-285.
19. Meylan F, Richard AC, Siegel RM. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev. 2011;244(1):188-196.
20. Schreiber TH, Wolf D, Tsai MS, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010; 120(10):3629-3640.
21. Wolf D, Schreiber TH, Tryphonopoulos P, et al. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation. 2012;94(6):569-574.
22. Leveson-Gower DB, Olson JA, Sega EI, et al. Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4- dependent mechanism. Blood. 2011;117(11): 3220-3229.
23. Cao YA, Wagers AJ, Beilhack A, et al. Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci USA. 2004; 101(1):221-226.
24. Chopra M, Riedel SS, Biehl M, et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis. 2013;34(6):1296-1303.
25. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature. 1978;272(5654):624-626.
26. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101(2):640-648.
27. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood. 2007;109(6):2649-2656.
28. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
29. Qiu P, Simonds EF, Bendall SC, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011;29(10):886-891.
30. Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687-696.
31. McGill R, Tukey JW, Larsen WA. Variations of box plots. Am Stat. 1978;32:12-16.
32. Rotolo JA, Stancevic B, Lu SX, et al. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood. 2009;114(17):3693-3706.
33. Maeda Y, Levy RB, Reddy P, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graftversus-host disease. Blood. 2005;105(5): 2023-2027.
34. Bäuerlein CA, Riedel SS, Baker J, et al. A diagnostic window for the treatment of acute graftversus-host disease prior to visible clinical symptoms in a murine model. BMC Med. 2013;11: 134.
35. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;108(4):1291-1297.
36. Magenau JM, Qin X, Tawara I, et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010;16(7):907-914.
37. Fujioka T, Tamaki H, Ikegame K, et al. Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013; 48(6):859-864.
38. Muriglan SJ, Ramirez-Montagut T, Alpdogan O, et al. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J Exp Med. 2004; 200(2):149-157.
39. Levine JE. Implications of TNF-a in the pathogenesis and management of GVHD. Int J Hematol. 2011;93(5):571-577.
40. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versushost disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122.
41. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007; 7(8):585-598.
42. Martelli MF, Di Ianni M, Ruggeri L, et al. HLAhaploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014; 124(4):638-644.
43. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res. 2010;46(1-3):79-93.
44. Khan SQ, Tsai MS, Schreiber TH, Wolf D, Deyev VV, Podack ER. Cloning, expression, and functional characterization of TL1A-Ig. J Immunol. 2013;190(4):1540-1550.
45. Biener-Ramanujan E, Gonsky R, Ko B, Targan SR. Functional signaling of membrane-bound TL1A induces IFN-gamma expression. FEBS Lett. 2010;584(11):2376-2380.
46. Papadakis KA, Zhu D, Prehn JL, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18- induced IFN-gamma production by peripheral blood and mucosal CCR91 T lymphocytes. J Immunol. 2005;174(8):4985-4990.